CLNN News and Press, Clene Inc. From 11/07/23

2023-11-07 08:30:18 ET More on Clene Clene gains after $45M federal grant to study lead asset in ALS Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene For further details see: Clene GAA...

Reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8 ® in the RESCUE ALS open-label extension trial Reported statistically significant long-term survival benefit of 70% decreased ...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Clene Inc. (CLNN) is expected to report $-0.1 for Q3 2023

New research has demonstrated that it is possible to detect signs of Parkinson’s disease through the introduction of a synthetic compound into patients’ bodies. The research was carried out by scientists at the Florey Institute and Austin Health in Australia. The focus of the rese...

Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS In 2019, Clene’s drug candidate, CNM-Au8(R), was selected for the HEALEY ALS Platform Trial, with enrollment co...

Clene’s wholly-owned subsidiary, Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”) The study will monitor s...

Clene (NASDAQ: CLNN) , a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced that it has innovated its investigational drug, CNM-Au8(R), with nanotechnology. Clene is evaluating CNM...

In line with recent emphasis on the growing importance of nanotechnology in the US, Clene Nanomedicine innovated its investigational drug, CNM-Au8(R), using nanotechnology for the treatment of neurodegenerative disease Clene’s nanotechnological approach was recently recognized by the NIN...

Clene (NASDAQ: CLNN) , a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is featured in the latest Bell2Bell Podcast release. During the segment, podcast host Stuart Smith discusses the c...